Vimarsana
Biggest News Aggregation in the World

Page 2 - Alpmy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alpmy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alpmy Today - Breaking & Trending Today

Astellas Pharma (OTCMKTS:ALPMY) Sets New 12-Month Low at $11.63 - Vimarsana News

Astellas Pharma (OTCMKTS:ALPMY) Sets New 12-Month Low at $11.63

Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Free Report) reached a new 52-week low on Tuesday . The stock traded as low as $11.63 and last traded at $11.83, with a volume of 227767 shares changing hands. The stock had previously closed at $11.82. Analysts Set New Price Targets Separately, Jefferies Financial Group downgraded Astellas Pharma […]

Merck's Earnings Are Thursday. Here's What to Expect. - Vimarsana News

Merck's Earnings Are Thursday. Here's What to Expect.

Pharmaceutical stocks have generally fallen, partly because of regulatory concerns, but also because high interest rates have made the companies dividends...

Astellas Pharma (OTCMKTS:ALPMY) Sets New 1-Year Low at $12.45 - Vimarsana News

Astellas Pharma (OTCMKTS:ALPMY) Sets New 1-Year Low at $12.45

Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Free Report) shares reached a new 52-week low during trading on Thursday . The stock traded as low as $12.45 and last traded at $12.47, with a volume of 411433 shares. The stock had previously closed at $12.66. Analysts Set New Price Targets Separately, Jefferies Financial Group downgraded Astellas […]

Astellas Pharma Inc. (OTCMKTS:ALPMY) Sees Large Decrease in Short Interest - Vimarsana News

Astellas Pharma Inc. (OTCMKTS:ALPMY) Sees Large Decrease in Short Interest

Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Free Report) saw a large decrease in short interest during the month of September. As of September 30th, there was short interest totalling 5,100 shares, a decrease of 54.1% from the September 15th total of 11,100 shares. Based on an average daily volume of 213,800 shares, the short-interest ratio […]

Apellis Pharmaceuticals shares rally as competing eye treatment fails to impress analysts - Vimarsana News

Apellis Pharmaceuticals shares rally as competing eye treatment fails to impress analysts

Apellis Pharmaceuticals Inc. shares jumped 8% premarket on Tuesday after competitor Iveric Bio, a unit of Astellas Pharma Inc. on Monday released results of...